Kawasaki disease after vaccination: Reports to the vaccine adverse event reporting system 1990-2007

Pediatric Infectious Disease Journal

Volumn 28, Issue 11, 2009, Pages 943-947

  Hua, Wei ^a   Izurieta, Hector S ^a   Slade, Barbara ^b   Belay, Ermias D ^c   Haber, Penina ^b   Tiernan, Rosemary ^a   Woo, Emily Jane ^a   Iskander, John ^b   Braun, M Miles ^a   Ball, Robert ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

Author keywords

Kawasaki disease; Vaccine adverse event

Indexed keywords

DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HEPATITIS B VACCINE; DIPHTHERIA VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; MEASLES MUMPS RUBELLA VACCINE; PNEUMOCOCCUS VACCINE; ROTAVIRUS VACCINE;

ADULT; ARTICLE; CHILD; CONTROLLED STUDY; DIPHTHERIA; FEMALE; HEPATITIS B; HUMAN; INFANT; INFLUENZA; MAJOR CLINICAL STUDY; MALE; MEASLES; MORBIDITY; MUCOCUTANEOUS LYMPH NODE SYNDROME; MUMPS; PERTUSSIS; PNEUMOCOCCAL INFECTION; POLIOMYELITIS; PRESCHOOL CHILD; PRIORITY JOURNAL; RUBELLA; SCHOOL CHILD; TETANUS; UNITED STATES; VIRUS INFECTION;

EID: 70350560664     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e3181a66471     Document Type: Article

References (30)

1. Centers for Disease Control and Prevention. Kawasaki Syndrome. Available at: http://www.cdc.gov/kawasaki/. Accessed October 29, 2007
2. American Academy of Pediatrics. Kawasaki disease. In: Pickering LK, Baker CJ, Long SS, et al., eds. Red Book: 2006 Report of the Committee on Infectious Diseases. Elk Grove Village, IL: American Academy of Pediatrics; 2006.
3. Rowley AH, Shulman ST. Kawasaki syndrome. Clin Microbiol Rev. 1998; 11:405-414.
4. Rowley AH, Shulman ST. Kawasaki syndrome. Pediatr Clin North Am. 1999;46:313-329.
5. Belay ED, Holman RC, Clarke MJ, et al. The incidence of Kawasaki syndrome in West Coast health maintenance organizations. Pediatr Infect Dis J. 2000;19:828-832.
6. Yanagawa H, Nakamura Y, Yashiro M, et al. Incidence of Kawasaki disease in Japan: the nationwide surveys of 1999-2002. Pediatr Int. 2006;48:356-361.
7. Burns JC, Kushner HI, Bastian JF, et al. Kawasaki disease: a brief history. Pediatrics. 2000;106:E27.
8. Holman RC, Curns AT, Belay ED, et al. Kawasaki syndrome hospitaliza-tions in the United States, 1997 and 2000. Pediatrics. 2003;112:495-501.
9. Rowley AH, Shulman ST. New developments in the search for the etiologic agent of Kawasaki disease. Curr Opin Pediatr. 2007;19:71-74.
10. Burgner D, Harnden A. Kawasaki disease: what is the epidemiology telling us about the etiology? Int J Infect Dis. 2005;9:185-194.
11. Shulman ST, Rowley AH. Advances in Kawasaki disease. Eur J Pediatr. 2004;163:285-291.
12. Barron KS. Kawasaki disease: etiology, pathogenesis, and treatment. Cleve Clin J Med. 2002;69(suppl 2):SII69-SII78.
13. Freeman AF, Shulman ST. Recent developments in Kawasaki disease. Curr Opin Infect Dis. 2001;14:357-361.
14. Matsuno S, Utagawa E, Sugiura A. Association of rotavirus infection with Kawasaki syndrome. J Infect Dis. 1983;148:177.
15. Miron D, Fink D, Hashkes PJ. Kawasaki disease in an infant following immunisation with hepatitis B vaccine. Clin Rheumatol. 2003;22:461-463.
16. Treadwell TA, Maddox RA, Holman RC, et al. Investigation of Kawasaki syndrome risk factors in Colorado. Pediatr Infect Dis J. 2002;21:976-978.
17. U.S. Food and Drug Administration. Information Pertaining to Labeling Revision for RotaTeq. Available at: http://www.fda.gov/cber/products/ rotateq.htm. Accessed October 29, 2007.
18. Chen RT, Rastogi SC, Mullen JR, et al. The Vaccine Adverse Event Reporting System (VAERS). Vaccine. 1994;12:542-550.
19. Ellenberg SS, Chen RT. The complicated task of monitoring vaccine safety. Public Health Rep. 1997;112:10-20.
20. Varricchio F, Iskander J, DeStefano F, et al. Understanding vaccine safety information from the Vaccine Adverse Event Reporting System. Pediatr Infect Dis J. 2004;23:287-294. (Pubitemid 38508877)
21. MedDRA: Medical Dictionary for Regulatory Activities. The FDA Safety Information and Adverse Event Reporting Program. Available at: http:// www.fda.gov/medwatch/report/meddra.htm. Accessed October 29, 2007.
22. Evans SJ, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf. 2001;10:483-486.
23. Evans S. Statistical methods in signal detection. In: Mann RD, Andrews EB, eds. Pharmacovigilance. Chichester, UK: John Wiley and Sons; 2002.
24. Burns JC, Wiggins JW Jr, Toews WH, et al. Clinical spectrum of Kawasaki disease in infants younger than 6 months of age. J Pediatr. 1986;109:759-763.
25. Rosenfeld EA, Corydon KE, Shulman ST. Kawasaki disease in infants less than one year of age. J Pediatr. 1995;126:524-529.
26. Tsuchida S, Yamanaka T, Tsuchida R, et al. Epidemiology of infant Kawasaki disease with a report of the youngest neonatal case ever reported in Japan. Acta Paediatr. 1996;85:995-997.
27. Genizi J, Miron D, Spiegel R, et al. Kawasaki disease in very young infants: high prevalence of atypical presentation and coronary arteritis. Clin Pediatr (Phila). 2003;42:263-267.
28. Yanagawa H, Nakamura Y, Yashiro M, et al. Results of the nationwide epidemiologic survey of Kawasaki disease in 1995 and 1996 in Japan. Pediatrics. 1998;102:E65.
29. Begier EM, Langford CA, Sneller MC, et al. Polyarteritis nodosa reports to the vaccine adverse event reporting system (VAERS): implications for assessment of suspected vaccine-provoked vasculitis. J Rheumatol. 2004; 31:2181-2188.
30. US Food and Drug Administration. Guidance for Industry: Good Pharma-covigillance Practices and Pharmacoepidemiologic Assessment. Available at: http://www.fda.gov/cber/gdlns/pharmacovig.htm. Accessed October 29, 2007.